Sato Kei, Takeuchi Junko S, Misawa Naoko, Izumi Taisuke, Kobayashi Tomoko, Kimura Yuichi, Iwami Shingo, Takaori-Kondo Akifumi, Hu Wei-Shau, Aihara Kazuyuki, Ito Mamoru, An Dong Sung, Pathak Vinay K, Koyanagi Yoshio
Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Kyoto, Japan.
Viral Mutation Section, HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, Maryland, United States of America.
PLoS Pathog. 2014 Oct 16;10(10):e1004453. doi: 10.1371/journal.ppat.1004453. eCollection 2014 Oct.
Several APOBEC3 proteins, particularly APOBEC3D, APOBEC3F, and APOBEC3G, induce G-to-A hypermutations in HIV-1 genome, and abrogate viral replication in experimental systems, but their relative contributions to controlling viral replication and viral genetic variation in vivo have not been elucidated. On the other hand, an HIV-1-encoded protein, Vif, can degrade these APOBEC3 proteins via a ubiquitin/proteasome pathway. Although APOBEC3 proteins have been widely considered as potent restriction factors against HIV-1, it remains unclear which endogenous APOBEC3 protein(s) affect HIV-1 propagation in vivo. Here we use a humanized mouse model and HIV-1 with mutations in Vif motifs that are responsible for specific APOBEC3 interactions, DRMR/AAAA (4A) or YRHHY/AAAAA (5A), and demonstrate that endogenous APOBEC3D/F and APOBEC3G exert strong anti-HIV-1 activity in vivo. We also show that the growth kinetics of 4A HIV-1 negatively correlated with the expression level of APOBEC3F. Moreover, single genome sequencing analyses of viral RNA in plasma of infected mice reveal that 4A HIV-1 is specifically and significantly diversified. Furthermore, a mutated virus that is capable of using both CCR5 and CXCR4 as entry coreceptor is specifically detected in 4A HIV-1-infected mice. Taken together, our results demonstrate that APOBEC3D/F and APOBEC3G fundamentally work as restriction factors against HIV-1 in vivo, but at the same time, that APOBEC3D and APOBEC3F are capable of promoting viral diversification and evolution in vivo.
几种载脂蛋白B mRNA编辑酶催化多肽样蛋白3(APOBEC3),特别是APOBEC3D、APOBEC3F和APOBEC3G,可在HIV-1基因组中诱导G到A的超突变,并在实验系统中消除病毒复制,但它们在体内对控制病毒复制和病毒遗传变异的相对贡献尚未阐明。另一方面,一种HIV-1编码的蛋白,即病毒感染因子(Vif),可通过泛素/蛋白酶体途径降解这些APOBEC3蛋白。尽管APOBEC3蛋白已被广泛认为是对抗HIV-1的有效限制因子,但尚不清楚哪种内源性APOBEC3蛋白在体内影响HIV-1的传播。在这里,我们使用了一种人源化小鼠模型以及在负责特定APOBEC3相互作用的Vif基序中发生突变的HIV-1,即DRMR/AAAA(4A)或YRHHY/AAAAA(5A),并证明内源性APOBEC3D/F和APOBEC3G在体内发挥强大的抗HIV-1活性。我们还表明,4A HIV-1的生长动力学与APOBEC3F的表达水平呈负相关。此外,对感染小鼠血浆中病毒RNA的单基因组测序分析表明,4A HIV-1具有特异性且显著的多样性。此外,在感染4A HIV-1的小鼠中特异性检测到一种能够同时使用CCR5和CXCR4作为进入共受体的突变病毒。综上所述,我们的结果表明,APOBEC3D/F和APOBEC3G在体内从根本上作为对抗HIV-1的限制因子发挥作用,但同时,APOBEC3D和APOBEC3F能够在体内促进病毒的多样化和进化。